

Korea's Lunit collaborates with US-based Discovery Life Sciences to expand AI-powered tissue analysis for biopharma research

October 12, 2026 | News

To broaden global access to Lunit's AI-powered pathology platform



South Korea-based Lunit, a leading provider of AI for cancer diagnostics and precision oncology, has announced a strategic collaboration with Discovery Life Sciences, a global leader in biospecimens and specialty laboratory services, to expand the adoption of the Lunit SCOPE suite, the company's AI-powered pathology platform, across biopharmaceutical research.

Discovery brings more than 25 years of assay expertise and has delivered biomarker services for more than 2,000 clinical trial programs while currently supporting over 350 active trial programs through its end-to-end specialty laboratory services across the drug development lifecycle.

Through the collaboration, Discovery and Lunit will work together with biopharma clients to apply the Lunit SCOPE suite within Discovery's biomarker and tissue analysis workflows, tailoring AI-powered pathology to each program's design.

By pairing Discovery's global biospecimen network and specialty laboratory expertise with Lunit's AI-powered image analysis on client programmes, the companies aim to provide pharmaceutical and biotechnology companies with standardised, quantitative tissue insights that support clinical research, translational studies, and drug development. The collaboration is expected to broaden global access to Lunit's AI-powered pathology platform for biopharmaceutical researchers and organisations.

The companies also plan to expand AI-enabled tissue analysis services that help researchers generate deeper biological insights, improve the reproducibility of tissue-based analysis, and accelerate evidence generation throughout the drug development process.